Neurochem enrolls first patient in phase 3 European clinical trial for Alzhemed

By Jennifer Chiou

New York, Nov. 22 - Neurochem Inc. announced the enrollment of the first patient in its European phase 3 clinical trial on Alzhemed.

The randomized, double-blind, placebo-controlled and parallel-designed study is testing the safety and efficacy of Alzhemed, Neurochem's investigational product candidate for the treatment of Alzheimer's disease.

The company said it expects 930 mild-to-moderate Alzheimer's patients to take part.

"This phase 3 clinical trial for Alzhemed is, in my view, the one raising the most hope in Europe for the treatment of Alzheimer's disease," principal investigator Bruno Vellas said in a news release.

"Alzhemed's good tolerability profile and unique mechanism of action aimed at stopping the progression of the disease rather than targeting the symptoms are particularly interesting.

"The enthusiasm evidenced by the large attendance at our recent investigator meeting in Vienna for this phase 3 clinical trial illustrates the European medical community's interest in and the excitement about participating in this trial," Vellas said in the release.

Laval, Quebec-based Neurochem develops and markets therapeutics principally for neurological disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.